These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27005874)

  • 1. An exploratory study of the health harms and utilisation of health services of frequent legal high users under the interim regulated legal high market in central Auckland.
    Wilkins C; Prasad J; Wong KC; Rychert M; Graydon-Guy T
    N Z Med J; 2016 Mar; 129(1431):51-8. PubMed ID: 27005874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
    Rychert M; Wilkins C; Parker K; Witten K
    Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do police arrestees substitute legal highs for other drugs?
    Wilkins C; Parker K; Prasad J; Jawalkar S
    Int J Drug Policy; 2016 May; 31():74-9. PubMed ID: 26948501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand.
    Gee P; Richardson S; Woltersdorf W; Moore G
    N Z Med J; 2005 Dec; 118(1227):U1784. PubMed ID: 16372033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the prohibition of benzylpiperazine (BZP) 'legal highs' on the prevalence of BZP, new legal highs and other drug use in New Zealand.
    Wilkins C; Sweetsur P
    Drug Alcohol Depend; 2013 Jan; 127(1-3):72-80. PubMed ID: 22819869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
    Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
    Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Trends in Alcohol and Other Drug Use Among Police Detainees in New Zealand, 2010-2015.
    Wilkins C; Prasad J; Parker K; Rychert M; Barnes HM
    Curr Top Behav Neurosci; 2017; 34():161-172. PubMed ID: 28434182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of New Zealand's 2008 prohibition of piperazine-based party pills on young people's substance use: results of a longitudinal, web-based study.
    Sheridan J; Dong CY; Butler R; Barnes J
    Int J Drug Policy; 2013 Sep; 24(5):412-22. PubMed ID: 23499366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
    Macfarlane V; Christie G
    Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of high availability of methamphetamine, cannabis, LSD and ecstasy in New Zealand: Are drug dealers promoting methamphetamine rather than cannabis?
    Wilkins C; Romeo JS; Rychert M; Prasad J; Graydon-Guy T
    Int J Drug Policy; 2018 Nov; 61():15-22. PubMed ID: 30347325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "They're legal so they're safe, right?" What did the legal status of BZP-party pills mean to young people in New Zealand?
    Sheridan J; Butler R
    Int J Drug Policy; 2010 Jan; 21(1):77-81. PubMed ID: 19321329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study.
    Hobbs M; Patel R; Morrison PD; Kalk N; Stone JM
    J Psychopharmacol; 2020 Jun; 34(6):648-653. PubMed ID: 32108548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: a case of effective industry self-regulation?
    Wilkins C; Sweetsur P
    Int J Drug Policy; 2010 Jan; 21(1):86-90. PubMed ID: 19359158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006-2009.
    Wilkins C; Sweetsur P; Griffiths R
    Drug Alcohol Rev; 2011 May; 30(3):255-63. PubMed ID: 21545555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand.
    Wilkins C; Sweetsur P; Girling M
    Drug Alcohol Rev; 2008 Nov; 27(6):633-9. PubMed ID: 19378447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partying on? Life after BZP-based party pills.
    Green JA
    N Z Med J; 2008 Oct; 121(1283):35-42. PubMed ID: 18841183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Synthetic cannabinoids: A new addiction matrix].
    Scocard A; Benyamina A; Coscas S; Karila L
    Presse Med; 2017 Jan; 46(1):11-22. PubMed ID: 28063756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity from the recreational use of 1-benzylpiperazine.
    Gee P; Gilbert M; Richardson S; Moore G; Paterson S; Graham P
    Clin Toxicol (Phila); 2008 Nov; 46(9):802-7. PubMed ID: 18821145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
    Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
    Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users.
    Scott LA; Roxburgh A; Bruno R; Matthews A; Burns L
    Addict Behav; 2012 Sep; 37(9):1058-62. PubMed ID: 22607716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.